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Abstract 
Objective: MiR-486 and miR-146a are cardiomyocyte-enriched microRNAs that control cell survival and self-reg-
ulation of inflammation. These microRNAs are released into circulation and are detected in plasma or in circulating 
exosomes. Little is known whether heart failure affects their release into circulation, which this study investigated.
Results: Total and exosome-specific microRNAs in plasma of 40 heart failure patients and 20 controls were prepared 
using the miRVana Kit. We measured exosomal and total plasma microRNAs separately because exosomes serve as 
cargos that transfer biological materials and alter signaling in distant organs, whereas microRNAs in plasma indicate 
the level of tissue damage and are mostly derived from dead cells. qRT-PCR was used to quantify miR-486, miR-146a, 
and miR-16. Heart failure did not significantly affect plasma miR-486/miR-16 and miR-146a/miR-16 ratio, although 
miR-146a/miR-16 showed a trend of elevated expression (2.3 ± 0.79, p = 0.27). By contrast, circulating exosomal 
miR-146a/miR-16 ratio was higher in heart failure patients (2.46 ± 0.51, p = 0.05). miR-146a is induced in response 
to inflammation as a part of inflammation attenuation circuitry. Indeed, Tnfα and Gm-csf increased miR-146a but not 
miR-486 in the cardiomyocyte cell line H9C2. These results, if confirmed in a larger study, may help to develop circulat-
ing exosomal miR-146a as a biomarker of heart failure.
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Introduction
Heart failure with reduced ejection fraction (EF) is a 
major cardiovascular disease and contributes signifi-
cantly to healthcare expenditure in the United States [1]. 
Currently, five million Americans are affected by heart 
failure and an additional 500,000 are diagnosed each year 
[2]. Five-year survival rate from heart failure is 50% [2]. 
Persistent aberrant interplay of various components of 
the immune system could lead to heart failure [3]. Many 
changes in the composition of biofluids after heart failure 
could result from damaged heart tissue or due to immune 
and non-immune-dependent systemic response to heart 
failures. These changes in biofluids can be exploited as 
biomarkers of disease course and response to therapy.
MicroRNAs (miR) are a class of short RNA molecules, 
which negatively regulate gene expression by targeting 
the 3′ untranslated region of specific mRNA [4]. Micro-
RNAs in circulation have been studied as biomarkers of 
cardiac pathophysiology [5, 6]. MicroRNAs from cells 
are released passively into circulation by damaged tissue 
or actively through exosomes [7]. MicroRNAs in circu-
lation are predominantly exosomes/microvesicles-free 
and likely byproducts of dead cells without any biologi-
cal activity [8]. By contrast, microRNAs in exosomes are 
transferred into cells in distant organs and actively mod-
ulate signaling in recipient cells [9, 10]. Because both free 
and exosomal microRNAs are relatively stable in circula-
tion, circulating microRNAs are being developed as bio-
markers of various diseases [11, 12]. We demonstrated 
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that circulating microRNAs, particularly miR-486, serve 
as biomarkers of systemic effects of cancer [13].
This study was initiated to determine whether miR-486 
serves as a biomarker of heart failure. Previous studies 
have shown elevated miR-486 in the plasma of patients 
with acute myocardial infarction [14] and coronary 
artery disease [15]. However, circulating level of miR-
486 in patients with chronic heart disease is unknown. 
miR-486 is expressed predominantly in heart and muscle 
[16] and targets proteins in myogenesis (MyoD), myo-
tube survival/differentiation (DOCK3/PTEN/AKT), car-
diomyocyte survival (PI3K/PTEN/pAKT), and cardiac 
progenitor cell proliferation networks [16–19]. miR-486 
is an integral part of myocardial homeostasis because it 
negatively regulates PIM1 kinase, which is essential for 
cycling of cardiac progenitor cells [16, 18, 19].
We included miR-146a in our study because heart 
failure is associated with inflammation, which induces 
miR-146a [20]. Induced miR-146a targets the same 
inflammatory molecules to attenuate inflammation. miR-
146a has a cardiomyocyte-protective function as expo-
sure to miR-146a increased cardiomyocyte viability and 
protection against oxidant stress [21, 22]. The purpose 
of this pilot study was to establish whether the levels of 
these two microRNAs are affected in heart failure.
Main text
Study population
We recruited 40 patients from outpatient cardiol-
ogy clinic and inpatient medicine service at Richard L. 
Roudebush VA Medical Center, Indianapolis, between 
August-2015 and February-2016 (Table 1). Indiana Uni-
versity IRB approved the study. Written consent was 
obtained from all subjects. Inclusion criteria included 
an EF  <  35% documented on most recent echocardio-
gram or NYHA class III or IV symptoms based on the 
assessment of patient’s primary cardiologist. Exclusion 
criteria included patients with a current or previous his-
tory of malignancy or inflammatory condition. We also 
recruited 20 veterans without a diagnosis of congestive 
heart failure or malignancy as controls. Demographics, 
clinical history, co-morbidities, echocardiographic and 
laboratory data were collected from electronic medi-
cal records.  Almost all study participants were males 
with whites being the predominant ethnic group. Mean 
age and BMI were lesser in the control group. The inci-
dence of hypertension, diabetes, coronary artery disease, 
and chronic kidney disease was significantly higher in 
the cases compared to controls (p  <  0.05). The preva-
lence of alcohol and drug use was not significantly dif-
ferent between two groups. Patients with heart failure 
had a mean EF of 22.2 ± 7.2%. Ischemia was most likely 
underlying etiology of heart failure (47.5%). Some degree 
of diastolic dysfunction was reported on 25% of the 
echocardiograms (Table 2). The majority of the patients 
with heart failure were receiving guideline-directed med-
ical therapy based on the etiology of heart failure and 
extent of depression in EF. 
Sample processing
Total miRNAs from 200 µl of plasma samples were pre-
pared using the miRVana miRNA isolation kit (AM1561, 
ThermoFisher Scientific). Total exosome isolation kit 
(ThermoFisher Scientific, Cat# 448445) was employed to 
extract exosomes from 200 μl plasma samples and miR-
NAs were isolated using the exosome RNA isolation kit 
(cat# 4478545). Exosome isolation kit has several qual-
ity control steps including precipitation of exosomes 
followed by wash and centrifugation steps to ensure 
purity of exosomes and quality of exosomes are similar 
to ultracentrifugation method [23]. Quantitative Reverse 
Transcription Polymerase Reaction (qRT-PCR) was used 
to quantify miR-486, miR-146a, and miR-16. Primers 
Table 1 Characteristics of study population at baseline
Cases Controls Overall p value
Number 40 20 60
Age—year (SD) 66.5 (10.5) 60.6 (15.7) 64.5 (12.6) 0.09
Sex—no. (%) 0.16
 Male 40/40 (100%) 19/20 (95%) 59/60 (98%)
Race—no. (%)
 White 31/40 (78%) 16/20 (80%) 47/60 (80%) 0.82
 African American 9/40 (22%) 3/20 (15%) 3/20 (15%) 0.50
 Others 1/20 (5%) 1/20 (5%) 0.16
Body mass index 
(SD)
30.4 (7.4) 28.8 (6.1) 29.9 (7.0) 0.40
Medical history—no. (%)
 Hypertension 32/40 (80%) 11/20 (55%) 43/60 (72%) 0.04
 Type 2 diabetes 23/40 (58%) 3/20 (15%) 26/60 (43%) 0.01
 Coronary artery 
disease
23/40 (58%) 2/20 (10%) 25/60 (42%) 0.00
 Chronic kidney 
disease
21/40 (53%) 1/20 (5%) 22/60 (37%) 0.00
 Alcohol abuse 3/40 (8%) 1/20 (5%) 4/60 (7%) 0.72
 Drug use 3/40 (8%) 2/20 (10%) 5/60 (8%) 0.74
Medications—no. (%)
 Aspirin 34/40 (85%) 6/20 (30%) 40/60 (67%) 0.00
 Beta-blocker 38/40 (95%) 7/20 (35%) 45/60 (75%) 0.00
 ACE/ARB 35/40 (88%) 2/20 (10%) 37/60 (62%) 0.00
 Spirinolactone 16/40 (40%) 0/20 (0%) 16/60 (27%) 0.00
 Statin 34/40 (85%) 9/20 (45%) 43/60 (72%) 0.00
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for qRT-PCR were purchased from ThermoFisher (hsa-
miR-486-5p, Cat#001278; hsa-miR-146a-5p, Cat#000468; 
hsa-miR-16-5p, Cat#000391). The expression levels of 
miR-486 and miR-146a were normalized to miR-16 using 
the  2−ΔΔCt method. Ratios between miR-486/miR-16 and 
miR-146a/miR-16 were calculated because there is no 
consensus on a microRNA that can be used as a normali-
zation control. We had shown that the most commonly 
used U6 small RNA is not a reliable normalization con-
trol for circulating total microRNAs [24]. Similar concern 
has recently been raised regarding normalization con-
trols for exosomal microRNAs [25]. We selected miR-16 
for normalization because it is present abundantly in cir-
culation and likely to be least variable as suggested by a 
previous study [26].
Statistical analysis
The primary null hypothesis for this study was that there 
would be no difference in miR-146a and miR-486 levels 
between patients with heart failure and controls. The 
sample size was determined based on results of a previ-
ous study measuring circulating miR-486 levels in breast 
cancer patients.  Using a two-sided Wilcoxon rank sum 
test, 14 subjects were needed in each group to ensure a 
power of 90%, with an alpha of 0.05.  However, because 
of absence of data in patients with cardiac conditions, 
40 subjects with disease and 20 healthy individuals were 
recruited. All continuous variables were expressed as 
mean ± SEM. Normalized expression levels of miR-486 
and miR-146a were converted to fold-changes. Wilcoxon 
signed ranked test was used for comparison between 
groups. A p value of  <  0.05 was considered to indicate 
statistical significance. SPSS 22.0 (Statistical Package for 
the Social Sciences, Chicago) and STATA 14.1 (Stata-
Corp. 2015.  Stata Statistical Software: Release 14. Col-
lege Station, TX: StataCorp LP) were used for statistical 
analysis.
Differences in microRNA levels between heart failure 
patients and controls
Raw CT values for each of the microRNAs are repre-
sented in Fig. 1a. Average fold-change for plasma levels of 
miR-486 and miR-146a showed a trend towards elevated 
expression in patients with heart failure (1.1 ± 0.27 and 
2.3 ±  0.79 respectively) but was not statistically signifi-
cant (0.82 and 0.14 respectively) (Fig.  1b). Circulating 
exosomes of heart failure patients contained a signifi-
cantly elevated levels of miR-146a compared to controls 
(2.46 ± 0.51, p = 0.05). A similar trend was noted with 
exosomal miR-486 (3.0 ±  0.95, p =  0.14). Due to small 
number of cases, subgroup analysis based on the degree 
of EF suppression, medical comorbidities or types of 
therapy was not performed.
Inflammatory cytokines induced miR‑146a but not 
miR‑486 in cardiomyocytes
To determine whether chronic inflammation associated 
with heart failure affects miR-146a and miR-486 expres-
sion in cardiomyocytes, we incubated the rat heart myo-
blast cell line H9C2 with Tnfα and Gm-csf (10  ng/ml) 
for 24  h and measured miR-146a/miR-16 and miR-486/
miR-16 ratio. Both cytokines increased miR-146a but not 
miR-486 (Fig. 1c).
MicroRNAs have a role in almost all aspects of cardiac 
pathophysiology [5]. A number of studies have exam-
ined circulating levels of microRNAs, including cardi-
omyocyte-enriched microRNAs, in plasma or serum 
of patients with acute heart failure. However, not many 
microRNAs are consistently changed across studies in 
patients with heart failure with the exception of cardiac-
specific miR-208. miR-208, which is involved in heart 
development, is upregulated in heart as well as in circula-
tion upon acute myocardial infarction [27–31] and coro-
nary artery disease [32]. A recent review emphasized the 
need for a larger clinical trial to develop clinically usable 
circulating microRNA biomarkers [6]. As the first step 
in this direction, we took a slightly different approach by 
measuring both free and exosome-encapsulated circulat-
ing microRNAs. Free circulating microRNA levels may 
show marked variability over time and likely depend-
ent on the rate of tissue repair, which may be affected 
by both age and comorbidity [8]. By contrast, exosomal 
microRNAs reflects overall health status, need not have 
to originate from the damaged tissue, and could account 
for exosomes released by hematopoietic cells in circula-
tion. Thus, this dual measurement permits detection 
of microRNAs released into circulation by dying cells 
and by other cell types in response to heart failure. Our 
study showed a significantly higher level of miR-146a in 
exosomes but not in plasma of patients with heart fail-
ure compared to controls. Previous studies have shown 
Table 2 Characteristics of heart failure patients
All values are expressed as N (percent of total cases)
Plus minus values are mean ± SD
Variables
Ejection fraction 22.2 ± 7.2% (range 10–35%)
Presence of diastolic dysfunction
 None 30 (75%)
 Stage 1 or 2 06 (15%)
 Stage 3 or 4 04 (10%)
Etiology of heart failure
 Ischemic 19 (47.5%)
 Non ischemic 14 (35.0%)
 Unknown 07 (17.5%)
Page 4 of 6Beg et al. BMC Res Notes  (2017) 10:751 
elevated plasma levels of miR-146a in patients with con-
tinuous flow left ventricular assist devices and in patients 
with peripartum cardiomyopathy (but not in patients 
with dilated cardiomyopathy) compared to healthy con-
trols but there has been limited efforts in measuring exo-
somal levels of this microRNA in heart failure patients 
[33, 34]. To our knowledge, there is only one study that 
examined microRNAs in circulating exosomes in canine 
models of heart failure [35].
Chronic low-grade inflammation in patients with heart 
failure has been known [3, 36]. One crucial player in this 
chronic inflammation is the feed-forward loop involv-
ing Nuclear Factor-κB (NF-κB), which increases pro-
inflammatory cytokines such as TNF-α, IL-1, IL-6, and 
IFN-γ and these cytokines, in turn, activate NF-κB [37]. 
Previous studies have shown NF-κB-inducible expression 
of miR-146a, which negatively effects IL-1 and TNF-α 
receptors to attenuate inflammation [38]. Consistent 
with this possibility, a recent study has shown cardiopro-
tective effects of exosomal miR-146a derived from car-
diac progenitor cells [39]. Thus, the increased exosomal 
level of miR-146a levels in heart failure patients is likely 
Fig. 1 a Raw CT values of microRNA measurements in plasma and exosomes. b Levels of miR-486 and miR-146a in plasma and exosomes of 
patients experiencing heart failure (n = 40) compared to healthy controls (n = 20). Fold changes indicate ratio between indicated test microRNA 
versus abundantly and ubiquitously expressed/released miR-16. c The effects of Tnfα and Gm-csf on miR-146a and miR-486 expression in H9C2 
cardiomyocytes. Cells maintained in DMEM plus 10% FBS were treated with Tnfα and Gm-csf at a concentration of 10 ng/ml for 24 h and microRNA 
levels were measured. miR-146a/miR-16 (n = 4, *p < 0.05, control vs. cytokine treatment) and miR-486/miR-16 ratio is presented
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attributable to the interplay of various components of the 
inflammatory system in pathogenesis of heart failure.
Similar to miR-146a, miR-486 is a central component 
of the inflammatory hub as NF-κB reduces the levels of 
muscle-specific transcription factor MyoD, which regu-
lates miR-486 expression in skeletal muscle [17, 40]. 
Apart from MyoD, myocardin-related transcription fac-
tor (MRTF) positively regulates miR-486 expression [16]. 
MRTF is a part of the inflammatory network and balance 
between the activity of MRTF and MyoD under inflam-
matory condition determines overall miR-486 expres-
sion levels [41]. Our patient population showed a trend 
towards the elevated expression of miR-486 levels, which 
is consistent with other studies showing elevated circulat-
ing miR-486 in patients with acute myocardial infarction 
and coronary aortic disorders [14, 15]. Sample size may be 
a reason our results did not reach statistical significance.
Limitations
First, our sample size was small, although power calcula-
tions based on our previous study in breast cancer patients 
indicated sufficient power [13]. However, the aim of this 
study was to establish changes in levels of these heart and 
muscle-enriched microRNAs in patients with heart failure 
such that studies with much larger patient population can 
be planned in future. Second, our study didn’t compare 
microRNA levels with currently used biomarkers (BNP, 
NT-pro-BNP and Troponin). This was not included in the 
study initially because these markers are reflective of other 
pathways of heart failure namely myocyte stress and injury 
but not inflammation. Also, comparison studies involving 
hundreds if not thousands of patients would be required, 
if these markers are to be considered for clinical use. Third, 
these microRNA levels may be affected by other patholo-
gies and their underlying mechanisms that we haven’t 
learned yet. Since the majority of patients with heart fail-
ure have other morbidities (diabetes, hypertension and/
or renal failure) compared to healthy controls (p < 0.05), 
these confounding comorbidities, treatments, and as well 
as duration of the these comorbidities may affect circulat-
ing microRNA levels. Since these co-morbidities and heart 
failure co-exist in majority of patients, obtaining samples 
from patients suffering from only chronic heart failure 
may not be practical. Variations between patients with 
respect to time lapsed between initial diagnosis of heart 
failure and sample collection can additionally impact data 
interpretations Finally, microRNAs were measured at one 
time-point, which may fluctuate during the progression of 
the disease and during acute exacerbations. Thus, larger 
longitudinal studies involving measurement of microR-
NAs at multiple intervals starting from initial diagnosis, 
stable disease, and exacerbation may help to understand 
the fluctuation of levels with changes in disease state.
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